Peptide News Digest

NSW Warns After 1,180 ER Visits Tied to Unapproved Peptides, a Faster-Killing Antimicrobial Peptide, MOTS-c in Aging Eggs

NSW Health links 1,180 ER visits to unapproved peptides, a lab peptide kills drug-resistant Acinetobacter in minutes, and MOTS-c aids aging egg cells.

6 stories · Covering regulatory, research

Editor's Note

Monday's biggest story came from Australia, where the New South Wales health minister said emergency visits after taking unapproved peptides rose from 5 a month in July 2025 to almost 220 in September 2026, with BPC-157, TB-500, GHK-Cu, CJC-1295, and retatrutide among the products named. It lands the same week the U.S. moved a plan to loosen access to some of those same peptides through compounding pharmacies, a reminder that the products people buy online and the products a regulated pharmacy would make are not the same thing. The research news was all early: a machine-learning-tuned antimicrobial peptide cleared drug-resistant Acinetobacter in 15 minutes in the lab, MOTS-c improved energy production in aging ovarian cells and mouse eggs, and a scorpion peptide blocked part of the immune complement system and shrank heart damage in an animal model. On the GLP-1 side, a Toronto review laid out why GLP-1 and multi-hormone drugs may protect kidneys in people without diabetes, and a Nanjing rat study tested tirzepatide in pulmonary hypertension.

Regulatory

NSW Health Warns on Unapproved Peptides After 1,180 Emergency Visits, Rising From 5 a Month to Almost 220

New South Wales Health Minister Ryan Park warned on October 19, 2026 that 1,180 people attended NSW emergency departments after taking unapproved peptides between July 2025 and September 2026, with monthly presentations rising from 5 to almost 220, ABC News reported. NSW Health said unapproved products may contain BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295, and Park cited liver and kidney damage, allergic reactions, and severe vomiting. He urged people to use only peptides prescribed by a doctor and dispensed by a pharmacy, and said the issue would likely go to other Australian health ministers.

#gray-market #australia #bpc-157 #retatrutide #peptide-regulation
Research

Machine-Learning-Optimized Peptide CIT8 Clears Carbapenem-Resistant Acinetobacter in 15 Minutes in Lab Tests

Researchers at Houston Methodist Hospital and the National and Kapodistrian University of Athens reported in Frontiers in Microbiology on October 19, 2026 that CIT8, a 13-amino-acid antimicrobial peptide previously tuned by machine learning against MRSA, also kills drug-resistant Gram-negative bacteria. It inhibited 15 of 16 Acinetobacter baumannii strains at 4 µg/mL, including carbapenem-resistant clinical isolates, and at five times that dose cut about 50 million bacteria per mL to undetectable levels within 15 minutes by breaking their membranes. CIT8 and a mirror-image version also disrupted biofilms with relatively low toxicity to human cells; the work is in the lab.

#antimicrobial-peptides #antibiotic-resistance #acinetobacter #ai-drug-design
Research

MOTS-c Boosts Energy Production in Aging Ovarian Cells and Mouse Eggs in Taiwanese Lab Study

Researchers at Kaohsiung Veterans General Hospital and National Sun Yat-sen University reported in Reproduction and Fertility on October 19, 2026 that MOTS-c, a small peptide encoded in mitochondrial DNA, increased mitochondrial mass and ATP-linked respiration in a model of aging human granulosa cells, the cells that support developing eggs, without raising oxidative stress. In eggs from aged mice treated outside the body, MOTS-c improved maturation and lowered oxidative-stress signals, though results stayed below those of young eggs. MOTS-c is sold online as a wellness peptide; this is cell and mouse work only.

#mots-c #fertility #mitochondrial-peptides #preclinical
Research

Scorpion Peptide SjAPI-2 Blocks the Complement Immune Cascade by Binding C4 and Limits Heart Damage in an Animal Model

Researchers at Hubei University of Medicine reported in Biomolecules on October 19, 2026 that SjAPI-2, a small peptide from scorpion venom, inhibited the classical complement pathway, part of the immune system that can damage the body's own tissue, by binding the complement proteins C4 and C4b. Mapping showed a loop between residues K30 and V38 does the work, and the peptide limited heart muscle damage in an ischemia-reperfusion injury model. The authors describe it as the first anti-complement peptide reported from scorpions; the work is preclinical.

#venom-peptides #complement #scorpion-toxin #preclinical
Research

Toronto Nephrologists Review How GLP-1 and Multi-Hormone Drugs May Protect Kidneys in People Without Diabetes

Nephrologists at Sunnybrook Health Sciences Centre reviewed in the Journal of the American Society of Nephrology on October 19, 2026 how GLP-1 drugs and newer multi-hormone agents that also act on GIP, glucagon, or amylin receptors may protect the kidneys. They describe direct effects, such as increased sodium excretion and reduced kidney inflammation, and indirect ones through weight loss, lower blood pressure, and better heart failure. The authors note that evidence in people without diabetes so far comes from secondary kidney measures in obesity and heart trials, not from dedicated kidney trials.

#glp-1 #kidney-disease #tirzepatide #retatrutide
Research

Tirzepatide Reduced Blood Vessel Remodeling in a Rat Model of Pulmonary Arterial Hypertension

Researchers at Nanjing University-affiliated hospitals reported in Cells on October 19, 2026 that tirzepatide improved ultrasound measures of strain on the lung circulation and reduced remodeling of small lung arteries in an animal model of pulmonary arterial hypertension. In lab experiments, the drug lowered lactate buildup in artery smooth muscle cells through the AMPK/SIRT1 pathway and reduced a histone mark that drives the cells' growth. The authors called it a preclinical rationale for testing tirzepatide in pulmonary hypertension.

#tirzepatide #cardiovascular #preclinical

Related Guides